- Home
- CRDL vs ENTX Comparison
CRDL vs ENTX Comparison
Compare CRDL & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- ENTX
- Stock Information
- Founded
- CRDL 2017
- ENTX 2010
- Country
- CRDL Canada
- ENTX Israel
- Employees
- CRDL N/A
- ENTX N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRDL Health Care
- ENTX Health Care
- Exchange
- CRDL Nasdaq
- ENTX Nasdaq
- Market Cap
- CRDL 102.0M
- ENTX 90.2M
- IPO Year
- CRDL N/A
- ENTX 2018
- Fundamental
- Price
- CRDL $1.20
- ENTX $2.10
- Analyst Decision
- CRDL Strong Buy
- ENTX Strong Buy
- Analyst Count
- CRDL 3
- ENTX 1
- Target Price
- CRDL $9.00
- ENTX $10.00
- AVG Volume (30 Days)
- CRDL 274.8K
- ENTX 70.9K
- Earning Date
- CRDL 03-31-2025
- ENTX 03-07-2025
- Dividend Yield
- CRDL N/A
- ENTX N/A
- EPS Growth
- CRDL N/A
- ENTX N/A
- EPS
- CRDL N/A
- ENTX N/A
- Revenue
- CRDL N/A
- ENTX $99,000.00
- Revenue This Year
- CRDL N/A
- ENTX N/A
- Revenue Next Year
- CRDL N/A
- ENTX N/A
- P/E Ratio
- CRDL N/A
- ENTX N/A
- Revenue Growth
- CRDL N/A
- ENTX 607.14
- 52 Week Low
- CRDL $1.15
- ENTX $1.00
- 52 Week High
- CRDL $3.12
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- CRDL 41.60
- ENTX 40.77
- Support Level
- CRDL $1.15
- ENTX $2.20
- Resistance Level
- CRDL $1.51
- ENTX $2.49
- Average True Range (ATR)
- CRDL 0.10
- ENTX 0.22
- MACD
- CRDL -0.01
- ENTX -0.03
- Stochastic Oscillator
- CRDL 13.65
- ENTX 16.13
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.